In cholangiocarcinoma, the prognostic impact of IDH mutations is more complex and may be related to factors such as tumor differentiation and mutation type, whereas in gliomas, IDH mutations are typically associated with a better prognosis [18]. This evidence concerns the gene IDH1 and cholangiocarcinoma.